Metatron Announces LOI for Acquisition of a Private Cannabis Company and OTC Market Status Upgrade
ACCESSWIRE
DOVER, DE / ACCESSWIRE / July 18, 2017 / Metatron (OTC PINK: MRNJ), an emerging pioneer of releasing Marijuana & CBD-related apps on iTunes and Google Play, is pleased to announce it is preparing an LOI (Letter of Intent) for an acquisition of a Private Cannabis Company adding to its growing Cannabis Venture. Additionally, Metatron announces that it is now at current status on OTC markets website, as the company updated and provided the current information required.
Metatron intends to acquire a private cannabis company created by dedicated professionals who share a passion for mastering the art of cannabis cultivation and manufacturing. The Company seeks to offer dispensaries a wide variety of wholesale cannabis products sourced with the highest standards possible. With each consumer in mind, their mission is to distribute pure, potent, and flavorful cannabis products.
"This acquisition will place Metatron miles ahead of the competition by having a new Cannabis company in its portfolio of Cannabis product producing companies, as well as adding potential profits from the sale of raw Cannabis as a product to dispensaries for sales to the consuming public, where legal by law, and add to our effort in producing products that will aid in the fight of the Opioid crisis that is enveloping the entire world," stated CEO, Joe Riehl.
"Further information on this acquisition is forth coming and all needed SEC forms will be filed relating to this event in a timely manner," he said.
According to ArcView Research and Forbes, the Californian cannabis market, alone, is expected to reach $2.3B by 2020, and nationally increase 700% over the same time period.
The company is also pleased to announce a formal offer to Buzzlink, a cannabis e-commerce platform for dispensaries and consumers. Buzzlink.com will be financed partially by the issuance of preferred B series shares. For more information, please visit http://metatroninc.com/series-b/ or http://www.metatronstock.com/.
Metatron approved investors can acquire Series B shares in blocks of various sizes. The first round investors will receive the highest discount. Series B shares can be redeemed through the Company, are immune to reverse splits, and will convert at 1 B share to 50,000 common shares. Details available at http://metatroninc.com/series-b/ or http://www.metatronstock.com.
Metatron is partnering up with Nutraceutical and Skin Care company, Kyani, who have generated over $250,000,000 in sales worldwide. The company are also offering distributor positions for a limited time.
"These products are the best I have ever used and the business opportunity is amazing. I have seen many lives changed physically and financially for the better. Highly recommended," said CEO, Joe Riehl.
Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the company's operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's need for additional financing, which is not assured and which may result in dilution of shareholders, the company's status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS operating system, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation to update information contained in any forward-looking statement. Metatron does not grow, sell or distribute any substances that violate United States Law or the Controlled Substances Act.
